Richter expects 10-15% sales growth on the non-subsidized drug market in Russia business daily Vilaggazdasag reports. In the DLO system Richter sees US$ 40m turnover in 2007 versus some US$ 30m this year. Egis expect its total Russian sales to grow by 25-30% this year (ending on 30 September 2006). Egis sees its Russian sales to expand by 25% each years in the next three years.
Our view:
We see the companies practically maintained their original sales targets, and their view on a very healthy market environment in Russia. We expect no market reaction to the news.